A

Prasugrel blocks the platelet ADP P2Y12 receptor and is not a glycoprotein IIb/IIIa antagonist, whereas abciximab, tirofiban, and eptifibatide are classic GP IIb/IIIa inhibitors used intravenously during acute coronary interventions [Tantry, 2006, PMID 17107286; Cheng, 2002, PMID 12434710].